Hemostemix Inc. (TSXV:HEM, FSE:2VFO.F, OTCQB:HMTXF)
Hemostemix: Your Fountain of Youth
Hemostemix (TSXV: HEM; OTCQB: HMTXF) is a clinical-stage biotechnology company focused on developing and commercializing a proprietary autologous cell therapy to treat ischemic diseases. Three months after the GCFF healthcare event, we are excited to meet with Thomas Smeenk, CEO, and Co-founder of Hemostemix again for the latest updates. On Sep 14, Hemostemix announced the first of a series of 2021 video interviews with ACP-01 recipients: what the successful compassionate treatment of ischemic cardiomyopathy looks like after 13 years. Hemostemix’s lead technology, ACP-01, is expandable and is a pioneering approach to the treatment of ischemic diseases. It is also undergoing a phase II clinical trial for Critical Limb Ischemia, and the result will be coming up in Q3. Thomas shared with us some clinical trial stories in this episode as well. Watch today’s CEO Interview to learn more about Hemostemix.
About Hemostemix (TSXV: HEM; OTCQB: HMTXF)
Hemostemix is a publicly traded autologous stem cell therapy company. A winner of the World Economic Forum Technology Pioneer Award, the Company developed and is commercializing its lead product ACP-01 for the treatment of Critical Limb Ischemia, Peripheral Arterial Disease, Angina, Ischemic Cardiomyopathy, Dilated Cardiomyopathy and other conditions of ischemia. ACP-01 has been used to treat over 500 patients, and it is the subject of a randomized, placebo-controlled, double blind trial of its safety and efficacy in patients with advanced critical limb ischemia who have exhausted all other options to save their limb from amputation.For more information, please visit the website.
NAI500’s CEO Interview series is a program where we invite CEOs and senior executives of exciting public companies to uncover great investment opportunities for every day investors. If you don’t want to miss out on the great opportunities that we bring, subscribe to our YouTube channel and other social media channels below!
Disclaimer: NAI is being compensated for this content. Materials contained in this content are for information purposes only and is not intended to constitute an offering of securities in any jurisdiction. Nothing on this content should be construed as an offer, solicitation or recommendation to buy or sell products or securities.
